AMRX - AbbVie AstraZeneca targeted for improper use of drug patents
2023-12-14 14:26:24 ET
More on AbbVie, AstraZeneca, etc.
- GSK - Greenshoots In The Horizon
- AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition
- AstraZeneca Is Feeling The Weight Of The Market In 2023
- AbbVie, Amgen among firms targeted for latest Medicare inflation penalties
- Icosavax deal CVR based on FDA approval for IVX-A12, sales in EU, UK, Canada
For further details see:
AbbVie, AstraZeneca targeted for improper use of drug patents